TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Rate of glucose metabolism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Rate of confirmed response
Endpoint domain: Physiological/clinical
Primary endpoint: Patency of Graft Anastomosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in Treatment Management
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in Loneliness (ULS-8) scores from baseline
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Changes in Resilience (ER-11) scores from baseline
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Changes in Social Connectedness (MOS-SS) scores from baseline
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Changes in National and Cultural Identity (NATID) scores from baseline
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Integrated Asthma Quality of Life Questionnaire (AQLQ) Score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change from baseline Pocket depth (PD) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Three or more complete bowel movements per week at 10 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Improvement in Patient Assessment Constipation Quality of Life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Specificity of Ga 68-labeled PSMA-11 PET/CT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Positive Predictive Value (PPV) of Ga 68-labeled PSMA-11 PET/CT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Negative Predictive Value (NPV) of Ga 68-labeled PSMA-11 PET/CT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Surgical Outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Katz ADL
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in breath H2 production
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Molecular endometrial level using illumina RNA-seq
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Molecular endometrial level using immunohistochemistry
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Molecular endometrial level using flow cytometry
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BIS side difference
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety assessment through self-reported symptoms
Endpoint domain: Adverse events/effects
Primary endpoint: Safety assessment through standard laboratory testing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: microvascular function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Gastrointestinal symptoms score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Effectiveness of surgery as measured by the Michigan Hand Outcomes Questionnaire (MHQ) summary score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Borg Dyspnea Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in Behavior Rating Inventory of Executive Function (BRIEF)- Self-Report Form
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Challenge Task (CT) scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Wechsler Abbreviated Scale of Intelligence- Second Edition (WASI-II), block design subtest
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Safety of withholding anticoagulants
Endpoint domain: Adverse events/effects
Primary endpoint: Number of night time voids
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Proportion of patients with breastfeeding completed at 6 months
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Changes in Epworth sleepiness scale
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Changes in SF-36
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Changes in Pittsburgh Sleep Quality Index (PSQI)
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Brain biochemistry response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Neonatal Hyperbilirubinemia requiring phototherapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neonatal hemoglobin concentration 24-48 h postpartum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Neuropsychiatric inventory - nursing home version (NPI-NH)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Occurrence of diseases
Endpoint domain: Mortality/survival
Primary endpoint: Improvement in myocardial perfusion/viability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Upper Limb Impairment: Motor Activity Log (MAL) Amount of Use (AOU)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Upper Limb Impairment: Motor Activity Log (MAL) Quality of Use (QOU)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hemoglobin a1C
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change from baseline in CVD Risk - Life's Simple Seven
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change from baseline in PROMIS V1.2 - Global Health
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change from baseline in Difficulties in Emotional Regulation (DERS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Percentage of Participants Achieving IGA of 0 or 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urge to Smoke scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Ocular vascularization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Hand Eczema Severity Index (HECSI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Presence of Adenovirus, Enterovirus and/or Parvovirus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Free and total plasma concentrations of ropivacaine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Renal function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change in Substance Use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in HIV Risk Behaviors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in treatment adherence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Comparison of NIPD results to standard test results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to radiological progression free survival (PFS) rate
Endpoint domain: Mortality/survival
Primary endpoint: quantification of biofilm
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Tolerated Dose (MTD) of dexanabinol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of adverse events (AEs) in patients receiving dexanabinol monotherapy
Endpoint domain: Adverse events/effects
Primary endpoint: Number of adverse events (AEs) in patients receiving dexanabinol in combination with standard chemotherapies
Endpoint domain: Adverse events/effects
Primary endpoint: Change in serum oxidized LDL-cholesterol concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Participants Experiencing Symptoms
Endpoint domain: Adverse events/effects
Primary endpoint: Number of patients experiencing drug limiting toxicity (DLT)
Endpoint domain: Adverse events/effects
Primary endpoint: Cumulative incidence of transplant-related nonrelapse mortality
Endpoint domain: Mortality/survival
Primary endpoint: Subjective Usability Reporting
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Comparative Subjective Reported Comfort
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: safety and efficacy of Tretinoin and Pioglitazone HCL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase in Na level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Gastrointestinal functional outcomes (LARS questionnaire)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Gastrointestinal functional outcomes (GIQLI by Eypasch questionnaire)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Rate of Dose-Limiting Toxicities (DLTs)
Endpoint domain: Adverse events/effects
Primary endpoint: Objective Response Rate (ORR) according to RECIST version 1.1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Experiencing Solicited Local or Systemic Reactogenicity
Endpoint domain: Adverse events/effects
Primary endpoint: Escitalopram concentration in blood serum (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Yield of capsule endoscopy for diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Adverse reactions/events rate
Endpoint domain: Adverse events/effects
Primary endpoint: Seroconversion rate of Neutralizing antibodies against SARS-CoV-2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Seroconversion rate of IgG antibodies against SARS-CoV-2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Current practice and capacity regarding colorectal cancer screening
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Capacity for colonoscopy and diagnostic follow-up
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Care coordination and communication with primary care providers
Endpoint domain: Resource use
Endpoint subdomain: Delivery of care
Primary endpoint: Proportion of patients with IIEF-EF score ≥22
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Positive ctDNA detection by 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Positive ctDNA detection by 24 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Absence of detectable ctDNA or disease recurrence 6 months after commencing pembrolizumab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent Change From Baseline in Inflammatory Lesion Count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Changes in physical activity participation
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Extracellular mass (ECM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ratio of low/high frequencies of power spectral density of R-R intervals
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Time to cessation of non-invasive positive pressure respiratory support
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: intensity of vessels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: intensity of muscle
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: intensity of air
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: prevention of hip fracture and other osteoporosis-related fracture events
Endpoint domain: Mortality/survival
Primary endpoint: Change from baseline in number of surfaces restored requiring new intervention
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Adverse events in the first 3 days post vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: Antibody response to each of the vaccine strains 21 days post vaccination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Cure defined as lack of clinical, biochemistry or radiological signs of infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Overall responder rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gingival exposure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical crown length
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Discomfort with Others
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Intervention Feasibility and Acceptability
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Penn Emotion Recognition Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stop Distance Paradigm
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum drug concentration (Cmax) of Perindopril
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration versus time curve (AUC0-∞, AUC0-t) of Perindopril
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adult ADHD Investigator Symptom Rating Scale (AISRS) total score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: central blood pressure change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Overall Best Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Changes in gray matter structure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Time to resolution of hemodynamic instability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Intelligence Quotient
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: subsequent renal damage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Maximum Observed Plasma Concentration (Cmax) of XEN1101
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration-time curve (AUC) of XEN1101
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peripheral Oxygen Saturation (SpO2) During Total Sleep Time (TST)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: T Cell Infiltration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Rate of Patient Consent
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Proportion of Enrolled Patients that Completed the Intervention
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Latency to initiate smoking
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease in lesion count
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of residents with Myocardial Infarction and Unstable Angina
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reduction of arrhythmia burden
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Heart rate trend
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Increase in patients activity
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Reduction in Ichthyosis Area Severity Index (IASI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Total Number of Bacterial or Fungal Mucocutaneous Infections
Endpoint domain: Adverse events/effects
Primary endpoint: Composite of target vessel failure (TVF)
Endpoint domain: Mortality/survival
Primary endpoint: Test of Arm Selective Control
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Abilhand- Kids Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Gross Motor Function Classification System
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Berg Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tinetti Gait Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Up & Go Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: compliance with different classes of drugs
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Cumulative incidence of ipsilateral breast tumor recurrence
Endpoint domain: Mortality/survival
Primary endpoint: Cumulative incidence of breast cancer specific survival
Endpoint domain: Mortality/survival
Primary endpoint: Emotional impact (feeling of isolation)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Improvement in Patient Perceived Fatigue
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Increase in Hemoglobin ≥ 1 g/dL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in sedentary time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Respiratory status of neonates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Changes in 14C-UBT (Urea breath test)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: MLWHF score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Range of measured head motion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Range of attentive responses (accuracy in % correct response)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average response time to stimulus items
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of Serious Adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants who receive HCV test results
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of participants who receive HIV test results
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Maximum-tolerated dose (MTD) of sunitinib malate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inflammatory Markers Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Delivery to and replication within tumors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: changes of FPG
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: changes of HbA1c
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: changes of fasting insulin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: changes of OGTT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Death (cardiovascular/all cause)
Endpoint domain: Mortality/survival
Primary endpoint: Aortic valve replacement (TAVI or surgical AVR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Presence of SARS-CoV2 RNA in saliva
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Reduction in Total Tumor Volume of at Least 20%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Reduction of Pain/Symptoms as Measured by NDS
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Changes of medication adherence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Visual acuity (both eyes)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Score on the Hamilton Rating Scale for Depression (Ham-D)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Proportion of diabetic foot ulcers healed
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Successful rate without extra vascular damage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Surgical cure of prolapse repair
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Failure of prolapse repair
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Weeks of Continuous Cannabis Abstinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Propofol plasmatic levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mastication evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes